Safety of resuming anti-PD-1 in patients with...

Annals of Oncology 2017 / 10

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Pollack, M H, Betof, A, Dearden, H, Rapazzo, K, Valentine, I, Brohl, A S, Ancell, K K, Long, G V, Menzies, A M, Eroglu, Z, Johnson, D B, Shoushtari, A N
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx642
Date:
October, 2017
File:
PDF, 628 KB
english, 2017
Conversion to is in progress
Conversion to is failed